Germany – Pharmaceutical products – Patent_95.1_Aripiprazol_Abilify (Maintena)

Decision signals

First-pass opportunity review

These signals are calculated from the indexed fields. They help prioritize a review but do not replace eligibility checks in the official procurement documents.

Timing signal

29 days to indexed deadline

27 November 2026

Indexed data completeness

86%

Based on seven decision fields

Official title coverage

7 languages

Preserved from source-supplied versions

Classification signal

33600000

Medical equipment, pharmaceuticals and personal care products

90-day market activity

442 related notices

105 buyers in Germany / Pharma and laboratory

Buyer activity

13 indexed notices

Published by this buyer in the last 90 days

Market context

How this notice compares with the current market

Biderra found 442 pharma and laboratory notices from Germany in its rolling 90-day index. 23% publish an estimated value and 53% include at least one indexed deadline. This notice is currently active according to the deadline fields available in the source feed.

Official title versions

TED may publish the same notice title in several official languages. Biderra preserves the versions supplied in the source feed.

What Biderra adds

For notice 738584-2026, Biderra has normalized the contracting authority country as Germany, grouped CPV 33600000 under pharma and laboratory, compared the available deadline fields with today, measured field completeness, and preserved 7 source-supplied title versions. The official record remains decisive.